IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial
Kremer, Joel; Li, Zhan-Guo; Hall, Stephen; Fleischmann, Roy; Genovese, Mark; Martin-Mola, Emilio; Isaacs, John D.; Gruben, David; Wallenstein, Gene; Krishnaswami, Sriram; Zwillich, Samuel H.; Koncz, Tamas; Riese, Richard9; Bradley, John
刊名ANNALS OF INTERNAL MEDICINE
2013-08-20
159期:4页:253-+
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
资助者Pfizer ; Pfizer
研究领域[WOS]General & Internal Medicine
关键词[WOS]INADEQUATE RESPONSE ; JAK INHIBITOR ; METHOTREXATE ; CP-690,550 ; PLACEBO ; ADALIMUMAB ; MALIGNANCY ; EFFICACY ; SAFETY ; RISK
英文摘要

Background: Many patients with rheumatoid arthritis (RA) do not achieve adequate and safe responses with disease-modifying antirheumatic drugs (DMARDs). Tofacitinib is a novel, oral, Janus kinase inhibitor that treats RA.

Objective: To evaluate the efficacy and safety of tofacitinib in combination with nonbiologic DMARDs.

Design: 1-year, double-blind, randomized trial (ClinicalTrials.gov:NCT00856544).

Setting: 114 centers in 19 countries.

Patients: 792 patients with active RA despite nonbiologic DMARD therapy.

Intervention: Patients were randomly assigned 4:4:1:1 to oral tofacitinib, 5 mg or 10 mg twice daily, or placebo advanced to tofacitinib, 5 mg or 10 mg twice daily.

Measurements: Primary end points were 20% improvement in American College of Rheumatology (ACR20) criteria; Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4[ESR]) of less than 2.6; DAS28-4(ESR)-defined remission, change in Health Assessment Questionnaire Disability Index (HAQ-DI) score, and safety assessments.

Results: Mean treatment differences for ACR20 response rates (month 6) for the 5-mg and 10-mg tofacitinib groups compared with the combined placebo groups were 21.2% (95% CI, 12.2% to 30.3%; P < 0.001) and 25.8% (CI, 16.8% to 34.8%; P < 0.001), respectively. The HAQ-DI scores (month 3) and DAS28-4( ESR) less than 2.6 response rates (month 6) were also superior in the tofacitinib groups versus placebo. The incidence rates of serious adverse events for patients receiving 5-mg tofacitinib, 10-mg tofacitinib, or placebo were 6.9, 7.3, or 10.9 events per 100 patient-years of exposure, respectively. In the tofacitinib groups, 2 cases of tuberculosis, 2 cases of other opportunistic infections, 3 cardiovascular events, and 4 deaths occurred. Neutrophil counts decreased, hemoglobin and low-and high-density lipoprotein cholesterol levels increased, and serum creatinine levels had small increases in the tofacitinib groups

Limitations: Placebo groups were smaller and of shorter duration. Patients received primarily methotrexate. The ability to assess drug combinations other than tofacitinib plus methotrexate was limited.

Conclusion: Tofacitinib improved disease control in patients with active RA despite treatment with nonbiologic DMARDs, primarily methotrexate.

语种英语
资助者Pfizer ; Pfizer
WOS记录号WOS:000323421700015
引用统计
被引频次:123[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65841
专题北京大学第二临床医学院
作者单位1.Albany Med Coll, Albany, NY 12208 USA
2.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
3.Cabrini Med Ctr, Malvern, Vic, Australia
4.Metroplex Clin Res Ctr, Dallas, TX USA
5.Stanford Univ, Stanford, CA 94305 USA
6.Hosp Univ La Paz, Madrid, Spain
7.Newcastle Univ, Newcastle Biomed Res Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
8.Newcastle Tyne Hosp NHS Trust, Newcastle Upon Tyne, Tyne & Wear, England
9.Pfizer Inc, Groton, CT 06340 USA
10.Pfizer, New York, NY USA
推荐引用方式
GB/T 7714
Kremer, Joel,Li, Zhan-Guo,Hall, Stephen,et al. Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial[J]. ANNALS OF INTERNAL MEDICINE,2013,159(4):253-+.
APA Kremer, Joel.,Li, Zhan-Guo.,Hall, Stephen.,Fleischmann, Roy.,Genovese, Mark.,...&Bradley, John.(2013).Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial.ANNALS OF INTERNAL MEDICINE,159(4),253-+.
MLA Kremer, Joel,et al."Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial".ANNALS OF INTERNAL MEDICINE 159.4(2013):253-+.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Kremer, Joel]的文章
[Li, Zhan-Guo]的文章
[Hall, Stephen]的文章
百度学术
百度学术中相似的文章
[Kremer, Joel]的文章
[Li, Zhan-Guo]的文章
[Hall, Stephen]的文章
必应学术
必应学术中相似的文章
[Kremer, Joel]的文章
[Li, Zhan-Guo]的文章
[Hall, Stephen]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。